A new method for the determination of arylesterase activity in human serum using simulated body fluid

Atherosclerosis

Volumn 188, Issue 1, 2006, Pages 155-159

  Nus, Meritxell ^a   Sánchez Muniz, Francisco J ^a   Sánchez Montero, José M ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Arylesterase; Cardiovascular disease; Kinetics; Method; Serum; Simulated body fluid

Indexed keywords

BICARBONATE; BUFFER; CHLORIDE; ELECTROLYTE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ACCURACY; ARTICLE; BODY FLUID; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CONCENTRATION (PARAMETERS); ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MALE; OXIDATION; PRIORITY JOURNAL; REPRODUCIBILITY; RISK ASSESSMENT; SIMULATION; VALIDATION PROCESS;

BODY FLUIDS; CARBOXYLIC ESTER HYDROLASES; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PHENYLACETATES; SENSITIVITY AND SPECIFICITY;

EID: 33645321418     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2005.10.016     Document Type: Article

References (21)

1. Parthasarathy S., Barnett J., and Fong L.G. High-density lipoproteins inhibit the oxidative modification of low-density lipoprotein. Biochim. Biophys. Acta 1044 (1990) 275-283
2. Aviram M., Rosenblat M., Billecke S., et al. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic. Biol. Med. 26 (1999) 892-904
3. Mackness M.I., Mackness B., Durrington P.N., et al. Paraoxonase and coronary heart disease. Curr. Opin. Lipidol. 9 (1998) 319-324
4. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., and La Du B.N. Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions, a possible peroxidative role for paraoxonase. J. Clin. Invest. 101 (1998) 1581-1590
5. Yla-Hertuala S., Palinski W., and Rosenfeld M.E. Evidence for the presence of oxidatively modified low density lipoproteins in atherogenic lesions of rabbit and man. J. Clin. Invest. 84 (2000) 1086-1095
6. Canales A., and Sánchez-Muniz F.J. La paraoxonasa, ¿algo más que un enzima? (Paraoxanase, something more than an enzyme ?). Med. Clin. (Barc.) 121 (2003) 537-548
7. Abbott C.A., Mackness M.I., Kumar S., Boulton A.J.M., and Durrington P.N. Serum paraoxonase activity, concentration and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol. 15 (1995) 1812-1818
8. McElveen J., Mackness M.I., Colley C.M., Peard T., Warner S., and Walter C.H. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin. Chem. 32 (1986) 671-673
9. Harel M., Aharoni A., Gaidukov L., et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat. Struct. Mol. Biol. 11 (2004) 412-419
10. Eckerson H.W., Romson J., Wyte C., and La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 35 (1983) 214-227
11. Lorentz K., Wirtz W., and Weiß T. Continuous monitoring arylesterase in human serum. Clin. Chim. Acta 308 (2001) 69-78
12. Kokubo T., Kushitani H., and Sakka S. Solutions able to reproduce in vivo surface structure changes in bioactive glass-ceramic A-W. J. Biomed. Mater. Res. 24 (1990) 721-734
13. Takadama A., Hashimoto H., Mizuno M., Ishikawa K., and Kokubo T. Newly improved simulated body fluid. Key Eng. Mater. 255 (2004) 115-118
14. Oyane A., Onuma K., Ito A., Kim H.M., Kokubo T., and Nakamura T. Formation and growth of clusters in conventional and new kinds of simulated body fluids. J. Biomed. Mater. Res. 64 (2003) 339-348
15. Beltowski J., Wojcika G., and Marciniak A. Species- and substrate-specific stimulation of human plasma paraoxonase 1 (PON1) activity by high chloride concentration. Acta Biochim. Pol. 49 (2002) 927-936
16. Bardsley W.G. SIMFIT 5.4: a computer package for simulation, curve fitting statistical analysis in the life sciences (2004), Manchester University, Manchester, United Kingdom
17. Kim H.M., Miyazaki T., Kokubo T., and Nakamura T. Revised simulated body fluid. Key Eng. Mater. 192 (2001) 47-50
18. Oyane A., Kim H.M., Furuya T., Kokubo T., Miyazaki T., and Nakamura T. Preparation and assessment of revised simulated body fluids. J. Biomed. Mater. Res. 65 (2003) 188-195
19. Sarandol E., Serdar Z., Dirican M., and Safak O. Effects of red wine consumption on serum paraoxonase/arylesterase activities and on lipoprotein oxidizability in healthy-men. J. Nutr. Biochem. 14 (2003) 507-512
20. Azarsiz E., Kayikcioglu M., Payzin S., and Yildirim Sozmen E. PON1 activities and oxidative markers of LDL in patients with angiographically proven coronary artery disease. Intern. J. Cardiol. 91 (2003) 43-51
21. Sutherland W.H.F., Manning P.J., de Jong S.A., Allum A.R., Jones S.D., and Williams S.M. Hormone-replacement therapy increases serum paraoxonase/arylesterase activity in diabetic postmenopausal women. Metabolism 50 (2001) 319-324